Stock Market News for October 23, 2026

At a glance

On October 23, 2026, Alnylam Pharmaceuticals reported Phase 1b data showing 60–64% mutant huntingtin reductions at the highest brezosiran dose; Oracle announced a $1 billion commitment to its partner ecosystem; Zymeworks struck a Roche collaboration with a $55 million upfront; Bolt Biotherapeutics agreed to acquire Prana Therapies and a $120 million private placement.

Drug trials and approvals

Alnylam Pharmaceuticals (ALNY) reported initial Phase 1b results showing mutant huntingtin reductions with brezosiran including mean month‑3 reductions of 60–64% in cerebrospinal fluid at the highest dose and individual reductions up to 83%.

Tango Therapeutics (TNGX) reported an 82% objective response rate with vopimetostat plus daraxonrasib in previously treated MTAP‑deleted, RAS‑mutant pancreatic cancer patients, with median follow‑up 7.1 months at the August 20, 2026 cutoff.

Revolution Medicines (RVMD) presented exploratory Phase 3 analyses showing RASONQUE survival benefits and noted previously reported median overall survival of 13.2 months with RASONQUE versus 6.7 months with chemotherapy.

Zai Lab (ZLAB) reported an 81.8% confirmed response rate for zoci plus atezolizumab in first‑line extensive‑stage small cell lung cancer at the recommended Phase 3 dose, with estimated six‑month progression‑free survival of 81.9%.

Zymeworks (ZYME) entered into an exclusive global license and collaboration agreement with Roche for ZW209 and received a $55 million upfront payment, plus potential milestones up to $718 million and tiered royalties.

Deals and partnerships

Oracle (ORCL) announced a $1 billion commitment to expand PartnerNetwork benefits and incentives to support AI‑powered solutions and partner growth over the next four years.

Bolt Biotherapeutics (BOLT) acquired Prana Therapies and agreed to a concurrent private placement expected to raise $120 million (with up to $60 million more upon warrant exercise) to advance PRA‑216 into multiple inflammatory indications.

House of Doge (HODO) agreed to acquire McQueen Labs’ tokenization platform and credit assets to expand into tokenized yield vaults, with transaction terms and financing alternatives, including a proposed $100 million at‑the‑market program, not yet disclosed.

Earnings and guidance

SLB (SLB) reported third‑quarter 2026 revenue of $9.45 billion, up 5% sequentially and 6% year over year, with GAAP EPS of $0.49 and net income attributable to SLB of $735 million.

Infosys (INFY) reported second‑quarter revenue of $5,145 million, with AI revenue up 29% sequentially to account for 10.5% of revenue and operating margin at 21.0% for the quarter ended September 30, 2026.

First Citizens BancShares (FCNCA) reported third‑quarter 2026 net income of $606 million and approved an additional share repurchase plan authorizing up to $1.2 billion of Class A share repurchases through 2027.

LKQ (LKQ) announced preliminary third‑quarter 2026 results, withdrew full‑year guidance and named Salvatore A. Abbate its next chief executive and said revenue is expected near $3.32 billion with an expected continuing‑operations loss of $16 million to $32 million.

First Hawaiian (FHB) reported third‑quarter 2026 net income of $63.7 million, with diluted EPS of $0.52 and higher net interest income driven by increases in lending.

Operations and launches

Rocket Lab (RKLB) successfully launched its 98th Electron mission delivering three HAWK satellites for HawkEye 360 to a 520 km low Earth orbit and marking its 19th successful mission in 2026.

Dividends and shareholder actions

AI OKTO (AIOK) declared a one‑time special dividend of $3.50 per share, payable in cash or common shares with record date November 2, 2026 and expected payment on or about November 25, 2026.